Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
CM313 (SC)
The First People's Hospital of Lianyungang
Pemphigus Disease
1 trial -
CM336 Injection
The First People's Hospital of Lianyungang
Autoimmune Bullous Disease
1 trial -
CMOPΒ±R
The First People's Hospital of Lianyungang
NHL
1 trial -
CNSA-001
PTC THERAPEUTICS, INC.
Gastroparesis
1 trial -
CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule
CORCEPT THERAPEUTICS INC
Amyotrophic Lateral Sclerosis
1 trial -
CORT125134
CORCEPT THERAPEUTICS INC
Cushing's Syndrome
1 trial -
CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant
CORCEPT THERAPEUTICS INC
Gynecological Cancers
1 trial -
COYA 302
Coya Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
CP101
Finch Therapeutics Group
Clostridium Difficile Infection
1 trial -
CP101
Finch Therapeutics Group
Autism Spectrum Disorder
1 trial -
CPK850
Novartis Pharmaceuticals
Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
1 trial -
CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance
Lacuna Pharma Pty Ltd
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
1 trial -
CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion
Disc Medicine
Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)
1 trial -
CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN
The George Institute
Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
1 trial -
CT-011
United Therapeutics Europe Ltd
Multiple Myeloma
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Dementia With Lewy Bodies
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Early Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Mild to Moderate Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer Disease
3 trials -
CTI-1601
Larimar Therapeutics
Friedreich Ataxia
4 trials -
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer
1 trial -
CTX-009
Compass Therapeutics
Glioblastoma
1 trial -
CTX-009 (ABL001)
Compass Therapeutics
P1b: Advanced Solid Tumors
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources